PROGRAM SCHEDULE

MONDAY, JULY 20

10:00 am-10:35 am  Welcome and Opening Keynote Address

Welcome
Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA

Welcome and Introduction of Anthony Fauci
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Coronavirus infections: More than just the common cold
Anthony Fauci, National Institute of Allergy and Infectious Diseases (NIAID), Rockville, MD

10:35 am-10:50 am  Break

10:50 am-12:50 pm  Symposium 1: Intersection of the Biology of SARS-CoV-2 and Cancer

Introduction
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

The crosstalk between cellular transformation and the response to SARS CoV-2 infection
Benjamin tenOever, Icahn School of Medicine at Mount Sinai, New York, NY

Therapeutic targeting of TMPRSS2 and ACE2 as a potential strategy to combat COVID-19*
Irfan A. Asangani, University of Pennsylvania, Philadelphia, PA

Optimizing treatment for COVID-19 using computational modelling: Implications for cancer patients*
Lance L. Munn, Harvard Medical School, Boston, MA

A prediction of prostate cancer deaths spiking by SARS-CoV-2 infection*
Alakesh Bera, Uniformed Services University, Bethesda, MD

Systems approaches reveal shared pathways affected in SARS-CoV-2 infection and cancer

Poster presentations will be available throughout the meeting as an on-demand session beginning at 10:00 am EDT on Monday, July 20.
Nevan Krogan, University of California, San Francisco, CA

Closing Remarks / Discussion
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

10:50 am-12:50 pm  Symposium 2: Effects of Cancer Immunotherapies on Patients with COVID-19 (with and without Cancer)

Introduction
Elizabeth M. Jaffee, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD

COVID-19 in patients with lung cancers in New York City
Jia Luo, Memorial Sloan Kettering Cancer Center, New York, NY

Clinical characteristics and outcomes of Coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)*
Aljosja Rogiers, Melanoma Institute Australia, Sydney, NSW, Australia

COVID-19 treatment candidate hydroxychloroquine impairs tumor response to anti-PD1*
Simon Wabitsch, National Cancer Institute, Bethesda, MD

SARS-CoV-2 induces inflammatory cytokine release, which may be exacerbated by immune checkpoint blockade*
Layne Weatherford, University of Cincinnati, Cincinnati, OH

COVID-19 and cancer: A new perspective on cancer care in the era of immunotherapy
Leora Horn, Vanderbilt Ingram Cancer Center, Nashville, TN

Closing Remarks / Discussion
Elizabeth M. Jaffee, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD

12:50 pm-1:05 pm  Break

Poster presentations will be available throughout the meeting as an on-demand session beginning at 10:00 am EDT on Monday, July 20.
1:05 pm-2:05 pm  
**Forum 1: Regulatory and Operational Implications of Cancer Clinical Trial Changes During COVID-19**

Moderator: Keith T. Flaherty, Massachusetts General Hospital, Boston, MA
Panelists:
- José Baselga, AstraZeneca, Gaithersburg, MD
- James H. Doroshow, National Cancer Institute, Bethesda, MD
- Kristen M. Hege, Bristol-Myers Squibb, San Francisco, CA
- Paul G. Kluetz, U.S. Food and Drug Administration, Silver Spring, MD
- Patricia M. LoRusso, Yale University School of Medicine, New Haven, CT
- Caroline Robert, Gustave Roussy and Paris-Saclay University, Villejuif, France, Villejuif, France

1:05 pm-2:05 pm  
**Forum 2: Telehealth**

Moderator: Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
Panelists:
- Michael Businelle, Stephenson Cancer Center, Oklahoma City, OK
- Greg Garber, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA
- Ana Maria Lopez, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA
- Jennifer L. Malin, UnitedHealth, Minneapolis, MN
- Anna N. A. Tosteson, Norris Cotton Cancer Center, Lebanon, NH

2:05 pm-2:20 pm  
**Break**

2:20 pm-4:20 pm  
**Symposium 3: COVID-19 Vaccine Development**

Introduction
E. John Wherry, University of Pennsylvania, Philadelphia, PA

Rapid SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness
Kizzmekia S. Corbett, National Institutes of Allergy and Infectious Diseases (NIAID), Bethesda MD

Pan-HLA prediction of SARS-CoV-2 epitopes*
Katie M. Campbell, University of California, Los Angeles, CA

*Poster presentations will be available throughout the meeting as an on-demand session beginning at 10:00 am EDT on Monday, July 20.
Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes*  
Asaf Poran, BioNTech US, Cambridge, MA

A computational approach to identify a possible SARS-CoV-2 vaccine from receptor binding domain peptide sequence on spike glycoproteins*  
Majid Al-Zahrani, King Abdulaziz University, Jeddah, Saudi Arabia

Synthetic DNA for EID outbreaks including SARS-CoV2  
David Weiner, The Wistar Institute, Philadelphia, PA

Closing Remarks / Discussion  
E. John Wherry, University of Pennsylvania, Philadelphia, PA

2:20 pm-4:35 pm Symposium 4: Cancer Drug Repurposing to Treat COVID-19

Introduction  
Keith T. Flaherty, Massachusetts General Hospital, Boston, MA

Blocking Interleukin-8 to treat hospitalized patients with COVID-19  
Charles G. Drake, New York-Presbyterian/Columbia University Medical Center, New York, NY

Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalized patients: A case series*  
Tobias Janowitz, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Treatment with Tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection*  
Alexandra Cabanov, University of Chicago, Chicago, IL

A phase II trial to promote recovery from COVID-19 with endocrine therapy  
Catherine H. Marshall, Johns Hopkins University School of Medicine, Baltimore, MD

Inhibition of Bruton Tyrosine Kinase in patients with severe COVID-19  
Louis M. Staudt, National Cancer Institute, Bethesda, MD

Closing Remarks / Discussion  
Keith T. Flaherty, Massachusetts General Hospital, Boston, MA

Poster presentations will be available throughout the meeting as an on-demand session beginning at 10:00 am EDT on Monday, July 20.
**TUESDAY, JULY 21**

**10:00 am-10:35 am**  
**Keynote Address**

Introduction  
Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA

Flexibility to sustain solidity: Addressing new vulnerabilities in cancer at the time of COVID-19  
Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

**10:35 am-10:50 am**  
**Break**

**10:50 am-12:50 pm**  
**Symposium 5: Cancer Pathway Biologies Intersecting with COVID-19**

Introduction  
Dafna Bar-Sagi, New York University Langone Medical Center, New York, NY

Leveraging new insights from cancer drug discovery to target viral host factors  
Kevan Shokat, University of California, San Francisco, CA

Profound CD8 T cell responses towards SARS-CoV-2 OFR1ab in COVID-19 patients*  
Anastasia Gangaev, Netherlands Cancer Institute, Amsterdam, The Netherlands

COVIDOSE: Low-dose tocilizumab in the treatment of COVID-19 pneumonitis*  
Garth W. Strohbehn, University of Chicago, Chicago, IL

Preserving innate memory to overcome SARS-CoV-2 infection through the mevalonate pathway*  
Juan Luis Gomez Marti, University of Pittsburgh, Pittsburgh, PA

Treatment of COVID-19 pulmonary failure by targeting BTK  
Steven P. Treon, Dana-Farber Cancer Institute, Boston, MA

**Closing Remarks / Discussion**  
Dafna Bar-Sagi, New York University Langone Medical Center, New York, NY

*Poster presentations will be available throughout the meeting as an on-demand session beginning at 10:00 am EDT on Monday, July 20.*
Symposium 6: Continuity of Cancer Care

10:50 am-12:35 pm

Introduction
Gary K. Schwartz, Columbia University, New York, NY, and Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA

How a crisis informs management: Lessons about biology and social support
Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Changes implemented by U.S. oncology practices in response to COVID-19 pandemic: Initial report from the ASCO Registry on COVID-19 and cancer*
Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA

Cancer care telehealth utilization rates and provider attitudes in the wake of the novel Coronavirus pandemic: The Kaiser Permanente Northern California Experience*
Elad Neeman, San Francisco Medical Center, Kaiser Permanente Northern California, San Francisco, CA

Continuing cancer care through a coordinated disease outbreak response system
Lim Soon Thye, National Cancer Center, Singapore

Closing Remarks / Discussion
Gary K. Schwartz, Columbia University, New York, NY, and Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA

12:50 pm-1:05 pm

Break

1:05 pm-2:05 pm

Forum 3: How Will We Bring Patients Back to the Clinic

Moderator: Nancy E. Davidson, Fred Hutchinson Cancer Research Center, Seattle, WA
Panelists:
Howard A. Burris, Sarah Cannon Cancer Center, Nashville, TN
Lisa M. DeAngelis, Memorial Sloan Kettering Cancer Center, New York, NY
Catherine Liu, Fred Hutchinson Cancer Research Center, Seattle, WA
Patricia Spears, University of North Carolina, Chapel Hill, NC

*Poster presentations will be available throughout the meeting as an on-demand session beginning at 10:00 am EDT on Monday, July 20.
Josep Tabernero, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

1:05 pm-2:05 pm  Forum 4: How Cancer Researchers Are Applying Their Talents to COVID-19 Issues

Moderator: Dafna Bar-Sagi, New York University Langone Medical Center, New York, NY
Panelists:
   Anna D. Barker, The Ellison Institute of USC, Los Angeles, CA
   Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA
   Thomas J. Lynch, Fred Hutchinson Cancer Research Center, Seattle, WA
   Shiva Malek, Genentech, Inc., South San Francisco, CA
   J.T. Poirier, Perlmutter Cancer Center, NYU Langone Health, New York, NY

2:05 pm-2:20 pm  Break


Introduction
Marina Garassino, Fondazione IRCCS Instituto Nazionale dei Tumori, Milano, Italy, and Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA

COVID-19 pandemic and its effect on the psychological status of cancer patients and oncologists
Gabriella Pravettoni, University of Milan, Milan, Italy

Jessica Y. Islam, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

Patient reported outcomes of breast cancer patients during the COVID-19 outbreak in the epicenter of China: A cross sectional survey study*
Juanjuan Li, Renmin Hospital of Wuhan University, Wuhan, China

Scientia Potentia Est: How the Italian world of oncology changes in the COVID19 pandemic*
Rossana Berardi, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy

Poster presentations will be available throughout the meeting as an on-demand session beginning at 10:00 am EDT on Monday, July 20.
Impact of COVID-19 related psychosocial distress on health-related quality of life in rural cancer survivors*
Scherezade K. Mama, The Pennsylvania State University, University Park, PA

Ethics, cancer, and COVID
Arthur Caplan, NYU Langone Health, New York, NY

Closing Remarks / Discussion
Marina Garassino, Fondazione IRCCS Instituto Nazionale dei Tumori, Milano, Italy, and and Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA

2:20 pm-4:20 pm  Symposium 8: COVID-19 Diagnostics Development

Introduction
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

When cancer research goes viral
Douglas R. Lowy, National Cancer Institute, Bethesda, MD

Highly sensitive and full-genome interrogation of SARS-CoV-2 using multiplexed PCR enrichment followed by next-generation sequencing*
Chenyu Li, Paragon Genomics, Hayward, CA

CRISPR tests for SARS-CoV-2
Patrick D. Hsu, University of California, Berkeley, CA

Rapid isothermal SARS-CoV-2 detection using RT-LAMP
Brian Rabe, Harvard Medical School, Boston MA

Closing Remarks / Discussion
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

WEDNESDAY, JULY 22

10:00 am-12:15 pm  Symposium 9: Health Inequities and Disparities in the COVID-19 Pandemic

Introduction
Clayton C. Yates, Tuskegee University, Tuskegee, AL

Poster presentations will be available throughout the meeting as an on-demand session beginning at 10:00 am EDT on Monday, July 20.
Potential insights into COVID-19 disparities from the science of cancer health disparities
John M. Carethers, University of Michigan, Ann Arbor, MI

Cancer and race: two important risk factors for COVID-19 incidence as captured by the COVID Symptom Study real-time epidemiology tool*
David A. Drew, Massachusetts General Hospital and Harvard Medical School, Bostons, MA

Outcomes by race for cancer patients hospitalized with SARS-CoV-2 infection*
Steven S. Chang, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI

Factors affecting COVID-19 outcomes in cancer patients: A first report from Guy’s Cancer Centre in London*
Saoirse Dolly, Guy's and St Thomas' NHS Foundation Trust and Kings Health Partners, London, England

Unemployment and cancer screening: Baseline estimates to inform healthcare provision in the context of COVID-19 economic distress*
Stacey Fedewa, American Cancer Society, Atlanta, GA

COVID19 and cancer health disparities in Indigenous Tribal Nations and communities of the American southwest
Cheryl L. Willman, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM

Closing Remarks / Discussion
Clayton C. Yates, Tuskegee University, Tuskegee, AL

10:00 am-12:00 pm  Symposium 10: Risk Factors and Comorbidities Resulting in Adverse Outcomes for Cancer Patients with COVID-19

Introduction
Lucile L. Adams-Campbell, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

Host genetics and susceptibility to COVID-19 infection
Helen Su, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD

COVID-19 severity and outcomes in hospitalized patients with cancer at a
New York City tertiary medical center: A matched cohort study*
Gagandeep Brar, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY

Using Real-World Data (RWD) from an integrated platform for rapid analysis of patients with cancer with and without COVID-19 across distinct health systems*
Shirish M. Gadgeel, Henry Ford Cancer Institute, Detroit, MI

Increased risk of COVID-19 related death among cancer survivors*
Jie Shen, Virginia Commonwealth University, Richmond, VA

Cancer and Covid-19: Are non-cancer risks the same?
Leora Horwitz, NYU Langone Health, New York, NY

Closing Remarks / Discussion
Lucile L. Adams-Campbell, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

12:15 pm-12:30 pm   Break

12:30 pm-1:30 pm   Forum 5: Public-Private Partnerships Poised to Address COVID-19

Moderator: Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA
Panelists:
  Ramy Ibrahim, Parker Institute for Cancer Immunotherapy, San Francisco, CA
  David R. Kaufman, Bill and Melinda Gates Foundation, Seattle, WA
  Andrew S. Plump, Takeda Pharmaceutical Company, Cambridge, MA
  Ellen V. Sigal, Friends of Cancer Research, Washington, DC
  Tal Z. Zaks, Moderna, Inc., Cambridge, MA

12:30 pm-1:30 pm   Forum 6: Health Disparities

Moderator: John D. Carpten, Keck School of Medicine of USC, Los Angeles, CA
Panelists:
  Vadim Backman, Northwestern University, Evanston, IL
  Rea Blakey, U.S. Food and Drug Administration Oncology Center of Excellence, Silver Spring, MD
  John M. Carethers, University of Michigan, Ann Arbor, MI
  Kevin Cassel, University of Hawai‘i Cancer Center, Honolulu, HI
  Lisa A. Newman, Weill Cornell Medicine, New York, NY

Poster presentations will be available throughout the meeting as an on-demand session beginning at 10:00 am EDT on Monday, July 20.
1:30 pm-1:45 pm    Break

1:45 pm-3:45 pm    Symposium 11: Cancer Prevention and Early Detection during the COVID-19 Pandemic

Introduction
Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA

Navigating the new normal: Trends shaping post-COVID-19 cancer care delivery
Lisa C. Richardson, Centers for Disease Control and Prevention, Atlanta, GA

Assessing the impact of the COVID-19 pandemic on cancer patients, survivors and caregivers*
Amy Leader, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA

Patient-reported impact of the COVID-19 pandemic on breast cancer screening, diagnosis, and treatment: A national survey*
Erica T. Warner, Massachusetts General Hospital, Boston, MA

Impact of COVID-19 on breast and prostate cancer screening and early detection in a large healthcare provider group*
Mara M. Epstein, University of Massachusetts Medical School, Worcester, MA

The effects of the COVID-19 pandemic on cancer prevention and control
Otis W. Brawley, Johns Hopkins University, Baltimore, MD

Closing Remarks / Discussion
Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA

1:45 pm-3:45 pm    Symposium 12: Epidemiology and Registries of COVID-19 and Cancer

Introduction
Gypsyamber D'Souza, Johns Hopkins University, Baltimore, MD

Understanding the impact of COVID in cancer patients through the COVID-19 and Cancer (CCC-19) and other COVID consortiums
Brian I. Rini, Vanderbilt-Ingram Cancer Center, Nashville, TN

Poster presentations will be available throughout the meeting as an on-demand session beginning at 10:00 am EDT on Monday, July 20.
High mortality among hospital-acquired COVID-19 infection in patients with cancer: An observational cohort study from Quebec and British Columbia
Arielle Elkrief, Centre de recherche de l'Université de Montréal, Montreal, QC, Canada

Risk of morbidity and mortality in COVID-19 patients with cancer
Naomi Alpert, Icahn School of Medicine at Mount Sinai, New York, NY

Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small cell lung cancer and other rare thoracic malignancies
Alessio Cortellini, University of L'Aquila, L'Aquila, Italy

Transmission and control of COVID-19
Justin Lessler, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Closing Remarks / Discussion
Gypsyamber D'Souza, Johns Hopkins University, Baltimore, MD

3:45 pm-4:00 pm Break

4:00 pm-4:35 pm Keynote Address

Introduction
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Genomic tracking of SARS-CoV-2 evolution and spread
Trevor Bedford, Fred Hutchinson Cancer Research Center, Seattle, WA

4:35 pm-4:50 pm Break

4:50 pm-6:00 pm Closing Session: Returning to Cancer Research During COVID-19
Moderator: Elizabeth M. Jaffee, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD

Introduction
Elizabeth M. Jaffee, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD

NCI’s role in ensuring cancer research progress amid a pandemic
Norman E. Sharpless, National Cancer Institute, Bethesda, MD

Poster presentations will be available throughout the meeting as an on-demand session beginning at 10:00 am EDT on Monday, July 20.
Panel Discussion / Q&A
Elizabeth M. Jaffee, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD
Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA
Norman E. Sharpless, National Cancer Institute, Bethesda, MD
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Closing Remarks
Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

*Poster presentations will be available throughout the meeting as an on-demand session beginning at 10:00 am EDT on Monday, July 20.*